Gerresheimer's Divestment Bounce Loses Steam as Investors Weigh Debt Relief Against Lingering Risks
Published on 08/09/2026 at 17:52 | Redaktion boerse-global.de
The euphoria that greeted Gerresheimer's €1.5bn divestment plan has faded noticeably. The pharmaceutical packaging specialist closed Friday's session at €26.34, down 0.83 percent on the day and 4.57 percent lower on the week. Over a 30-day horizon, the shares have shed 9.92 percent of their value — eroding a meaningful chunk of the 12.5 percent surge triggered on July 29, when the company unveiled its agreement to sell two business units to a consortium advised by Apax Partners LLP.
That initial jump reflected genuine relief. The disposal of Centor US Holding and the global Primary Packaging Plastics (PPP) operations, carrying a combined enterprise value of roughly €1.5bn, hands management a powerful tool to tackle a €1.9bn debt pile. The two divisions generated €570m in revenue last year with around 2,400 employees. CFO Wolf Lehmann framed the transaction as a milestone in optimising the group's capital structure, with deleveraging set to accelerate once the deals close — Centor by the end of fiscal 2026 and PPP in the first half of fiscal 2027.
A Balance-Sheet Fix With a Glass-Sized Hole
The market's attention has now shifted to what comes next. Speculation is building that Gerresheimer could emerge from this restructuring largely debt-free, particularly if the Moulded Glass business — which includes parts of the former Bormioli Pharma Group operations — also finds a buyer. Jefferies analyst Christopher Richardson, who kept a "Hold" rating and €26.80 price target, noted that the Centor sale was broadly anticipated by the market; the real catalyst investors are waiting for, he argued, would be a transaction involving Moulded Glass.
The balance-sheet relief is welcome, but it does not erase every concern. Critics point to last year's negative earnings per share and the unresolved BaFin investigation, which continues to hang over the stock as a reputational and regulatory overhang. The company's own guidance for the current fiscal year reflects the operational strain: revenue is expected to land in the lower half of the €2.3bn to €2.4bn range, with adjusted EBITDA margin between 17 and 18 percent and free cash flow of minus €50m to minus €100m, partly due to reduced factoring volumes.
Speaking of regulatory overhangs — UK employers face their own compliance pressures when it comes to workplace safety. A free toolkit with 41 ready-to-use templates and checklists helps you document risks properly and stay on the right side of the law. Download the free Risk Assessment Toolkit
Analysts Turn, Though Not in Unison
The analyst community has responded with a spectrum of views. The most dramatic shift came from UBS, where Olivier Calvet raised the price target from €12.90 to €28.50 and upgraded the stock from "Sell" to "Neutral" on August 4. His rationale: the divestments lower leverage sufficiently for Gerresheimer to meet certain credit covenants, removing what had been a significant risk ahead of a testing period in November.
The DZ Bank had already moved on July 29, upgrading from "Sell" to "Hold" and lifting its fair value from €16 to €30. Analyst Sven Kürten cited the relief provided by the disposals but maintained that a discount of nearly half to peers remains justified while uncertainties persist. JPMorgan stands apart with an "Overweight" stance, while Deutsche Bank and Jefferies have stayed at "Hold."
Institutional Money Moves in Opposite Directions
The divergence among analysts mirrors an equally telling split among major investors. Goldman Sachs crossed German disclosure thresholds in June and now holds around 20 percent of voting rights — though the bank clarified that a substantial portion of the position consists of financial instruments rather than physical shares, built up in the course of ordinary client business. Meanwhile, D. E. Shaw & Co. has increased its disclosed short position from 1.41 percent to 1.52 percent, signalling that not everyone shares the optimism.
What's on the Calendar
Investors have a clear timeline to work with. The annual general meeting is scheduled for September 1, 2026, to be held virtually in Düsseldorf, with votes on management discharge, the compensation system and supervisory board elections. First-quarter results for the new fiscal year are expected in August, half-year figures in September or October, and third-quarter numbers in October. The company also announced on July 24 that a new tubular glass plant in Zhenjiang Dagang, China, has commenced operations — adding capacity for primary packaging of injectable drugs, creating around 300 jobs and deepening a two-decade-old joint venture with Shuangfeng Glass.
Despite the recent pullback, the stock still trades 7.33 percent above its 200-day moving average — evidence that the post-deal rally, while diminished, has not fully evaporated. The coming months will determine whether the deleveraging story can outweigh the operational and regulatory questions that continue to shadow the shares.
